# Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Source: https://onco.cc/trials/nct05563844/  
OnCo record `nct05563844` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PM 8.4 mg/m^2 in diffuse large B-cell lymphoma, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.

## Summary

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) is a phase 2 interventional study registered as NCT05563844 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 74 participants enrolled, started 2022-11-08 and due to reach its primary completion in 2026-12-30. Interventions recorded: PM 8.4 mg/m^2 and PM 11.2 mg/m^2.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05563844
- Phase: 2
- Setting: An Open-label, Multi-center Phase II Clinical Study on the Efficacy and Safety of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
- Enrolled: 74

## Sources

- ClinicalTrials.gov NCT05563844: https://clinicaltrials.gov/study/NCT05563844

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- companies: [Chengdu Zenitar Biomedical Technology](https://onco.cc/companies/chengdu-zenitar-biomedical-technology/)

---
JSON: https://onco.cc/api/v1/entities/nct05563844.json